Introduction
Hematopoietic stem cells (HSC) constitute an ideal target for gene therapies since they can be efficiently transduced ex vivo, and upon transplantation they can repopulate the hematopoietic system for the entire life of an individual. Recent improvements in retroviral vector design and gene transfer protocols have resulted in high rates of transgene expression and repopulation by transduced hematopoietic cells both in non-human primates 1 and in human NOD/scid repopulating cells (SRC). [2] [3] [4] [5] Although considerable progress has been made in stem cell gene therapy over the last 10 years, many important issues remain unresolved. These include the loss of engrafting and repopulating ability associated with ex vivo manipulation of the graft, the potential immune responses to cells expressing transgenes, and the long-term silencing of transgene expression. Another important limitation of stem cell gene therapy is the need for myeloablation for a competitive engraftment of the transduced cells in the absence of a selective advantage in vivo. Transplantation of hematopoietic cells usually requires highly toxic preparative treatments (conditioning) aimed primarily to ablate the tumor in patients with cancer. Such prepara-
gene-expressing cells were found in the grafted hematopoietic cells of all groups of mice, regardless of the dose of TBI administered or the level of engraftment achieved. This suggests that the engrafted animals could become tolerant to the transgene product (enhanced green fluorescent protein, EGFP). Our results indicate that TBI facilitates the engraftment of manipulated hematopoietic cells in a dosedependent manner, that mice engrafted with EGFP + hematopoietic cells probably acquire tolerance to EGFP, and that increasing the graft size and reducing the ex vivo manipulation required for retroviral gene transfer of hematopoietic cells also enhances their engrafting potential.
Gene Therapy (2002) 9, 1472-1479. doi:10.1038/sj.gt.3301826 tive treatments are also myelotoxic and are responsible for a large proportion of the morbidity and mortality associated with hematopoietic cell transplantation in humans. For this reason, the search for minimal myeloablative and/or immunosuppressive treatments that allow long-term engraftment of the transduced HSC in the recipients is urgently required for the development of stem cell gene therapies for non-malignant diseases. 6, 7 In the late 1970s, Slavin et al 8, 9 showed that chimerism induced by infusion of allogeneic marrow after total lymphoid irradiation was associated with tolerance to skin grafts of the same donor type. More recent evidence suggests that stable mixed hematopoietic chimerisms can be induced in non-myeloablated animals receiving only immunosuppression before the infusion of allogeneic HSC [10] [11] [12] or by increasing the number of cells transplanted. 13, 14 Engrafted animals usually become tolerant to the donor cells and do not reject subsequent grafts from the same donor. 15, 16 This concept is highly relevant not only in the field of organ transplantation, but also for hematopoietic and non-hematopoietic cell and gene therapies to succeed since immune tolerance to antigens encoded by transgenes is critical for long-term survival of the transduced cells in vivo. 17, 18 Whether the long-term engrafting and repopulating potential of murine BM cells can be maintained or enhanced when cultured ex vivo is still controversial. Some studies report a reduced engraftment of ex vivo expanded murine BM cells, [19] [20] [21] [22] whereas other authors have shown that this potential can be maintained or even increased ex vivo. [23] [24] [25] Engraftment also depends on the graft size. Transplantation of larger doses of HSC in single or repetitive infusions was reported to result in higher levels of engraftment even in non-ablated mice. 14, 26, 27 Unfortunately, the number of cells used in some of these studies (each recipient receiving the BM content of the femorae and tibiae of up to 10 donor mice) makes this strategy unrealistic for clinical application. The present work was designed to investigate the influence of myeloablation, the graft size, and ex vivo manipulation on the engraftment and long-term transgene expression in the murine hematopoietic system, and to determine whether survival of hematopoietic cells expressing a potentially immunogenic gene can be obtained in recipients receiving little or no myeloablative treatment.
Results

NX-E/EGFP16 ecotropic cell line construction and transduction efficiency of BM murine cells
NXE-EGFP16 ecotropic cell line carrying the EGFP gene was generated as specified in Materials and methods. The integrity of the provirus was ensured by Southern blot and the absence of helper virus by the marker rescue assay. 28 EGFP expression and retroviral titer (about 1-2 × 10 6 infectious particles/ml on NIH-3T3 cells) have been stable for more than 2 years. Mouse donor BM cells were transduced as specified above giving an average in vitro efficiency of 22.9 ± 8.2% measured by FACS analysis 24 h after the second transduction cycle, before transplantation (n = 25). Efficiency of transduction measured by clonogenic assays reached 53.8 ± 15.9%, being the increase with respect to the FACS analysis results probably due to delayed transgene expression (data not shown).
Engraftment of donor transduced BM cells in recipient mice
Short-(40 days) and long-term (5 months) engraftment of donor hematopoietic cells were measured by analyzing the presence of CD45.1 + cells in the hematopoietic tissues of surviving mice 40 days (n = 98), and 5 months after transplantation (n = 96) ( Table 1 ). The analysis was performed in the peripheral blood (PB) of the animals for short-term engraftment and in PB, BM and spleen for long-term analysis. A FACS analysis of a representative sample is shown in Figure 1 . Figure 2 shows the shortterm engraftment measured in the PB, and the long-term engraftment in the PB and the BM. Engraftment levels in the spleen were similar to those observed in the PB (Table  1) . In general, short-term engraftment was higher than long-term engraftment measured in the PB. Similarly, the percentages of donor cells were always higher in the PB and spleen than in the BM (Table 1 ). There was a significant correlation (r was superior to 0.78 in all cases, data not shown) between the dose of TBI received and the level of hematopoietic engraftment both at short and at long term. Only three out of nine evaluable non-ablated mice (all receiving 5 × 10 6 BM cells) had detectable donor engraftment in their PB 40 days after transplantation, at very low levels (0.5% on average). In mice transplanted with 0.5 × 10 6 transduced BM cells, macrochimerism
Gene Therapy (defined by the presence of more than 2.5% of cells of donor origin) 29 was observed only in those receiving 4 or more Gy.
Effects of graft manipulation
To determine whether the transduction procedure itself influenced the engrafting ability of the cells, 0.5 × 10 6 nonmanipulated BM cells obtained 5 days after 5-FU treatment were transplanted in groups of mice receiving the same TBI doses (0 to 9 Gy). Analysis of short-and longterm engraftment revealed that mice transplanted with fresh BM cells had, on average, three-fold higher levels of donor engraftment than mice transplanted with the same number of transduced cells ( Figure 2 ).
Effects of graft size
The effects of graft size on the level of hematopoietic engraftment was investigated by infusing a 10-fold larger dose (5 × 10 6 ) of transduced BM cells into groups of mice irradiated with 0, 2, 4 or 6 Gy of TBI (squares in Figure  2 ). Each recipient mouse received approximately the BM cell content of two femorae and tibiae of one 5-FU-treated donor mouse. On average, transplantation of 5 × 10 6 transduced BM cells resulted in eight-to 13-fold higher levels of engraftment than transplantation of 0.5 × 10 6 cells ( Table 2) .
Transduction of murine BM cells
Transduction efficiency was assessed in donor (CD45.1 + ) cells present in the PB of the recipient mice 40 days after transplantation, and in the CD45.1 + BM, PB and spleen of the recipient mice 5 months after transplantation. Results corresponding to the BM 5 months after transplantation are shown in Figure 3a . Transduction levels in the PB and the spleen were equivalent to those observed in the BM (data not shown). Additionally, transduction efficiency was measured in the CFU generated by the BM cells transduced ex vivo and the BM of the recipient mice 5 months after transplantation. On average, 22.9 ± 8.2% of the BM cells and 53.8 ± 15.9% of the CFU expressed EGFP after the ex vivo transduction (n = 25). In the engrafted animals, an average of 59.4 ± 26.5% of the BM cells of donor origin (CD45.1 + ) expressed EGFP 5 months after transplantation. Percentages of EGFP + cells in the PB, BM and spleen were similar in all groups of engrafted mice, irrespective of the amount of conditioning administered or the level of engraftment achieved. Moreover, direct comparison of EGFP expression in the marrow between microchimeric and macrochimeric mice also failed to show statistically significant differences (Figure 3b ). The same was true for the PB or the spleen (data not shown).
Multilineage transgene expression and engraftment
Whether the transduced BM cells were capable of multilineage repopulation was investigated using lineage-specific phenotypic markers coupled to analysis of donor engraftment (CD45.1) and transgene expression (EGFP) in the recipient BM cells 5 months after transplantation. Analysis of murine lineage-specific markers including Gr-1 (granulocytes), Mac-1 (monocytes/macrophages), CD3 (T cells) and B220 (B cells) revealed the presence of EGFP + cell populations at similar levels in all lineages analyzed, indicating that transduced grafts had given rise to long-term multilineage repopulation (data not shown). 
Discussion
In the present study, we show that the levels of engraftment of non-manipulated and retrovirally transduced HSC are clearly dependent on the dose of myeloablation (TBI) administered before the transplant. Additionally, these results indicate that engraftment can be enhanced by increasing the number of cells transplanted and by reducing or avoiding the ex vivo manipuGene Therapy 
d. in the BM of the recipient mice, 5 months after transplantation. (a) According to the dose of TBI received, and (b) according to the level of engraftment observed (microchimeric mice (Ͻ2.5% of cells of donor origin in the BM) are compared with macrochimeric mice (Ն2.5% of cells of donor origin in the BM)). Differences among the different groups in (a) and in (b) are not statistically significant.
lation required for efficient retroviral transduction of these target cells using the currently available protocols. Although no engraftment could be detected in the nonablated recipients, we show that in this murine model, conditioning the recipients with a relatively low dose of TBI (2 or 3 Gy) can provide levels of engraftment of transduced hematopoietic cells that may be relevant for clinical applications. Interestingly, transgene-expressing cells were detected at similar proportions in all groups of mice, with engraftment levels in their marrow ranging from 0.05% to virtually 100% of donor cells. This strongly suggests that tolerance to EGFP was probably induced in these animals, and that, if this were the case, the threshold level of chimerism necessary to induce it was very low.
Transplantation of autologous or syngeneic hematopoietic cells is not limited by immune barriers, but rather by competition between the grafted and the endogenous hematopoietic cells. Engraftment in normal, non-ablated syngeneic mice has been reported, but only after transplantation of very high doses of hematopoietic cells. Infusion of 2 × 10 8 murine BM cells over a period of 5 days resulted in levels of engraftment in the BM of up to 40%. 14, 27 Unfortunately, this strategy cannot be applied to humans due to the limited number of hematopoietic cells that can be harvested using the current clinically available procedures. It is widely accepted that myeloablation facilitates engraftment of fresh and/or transduced syngeneic hematopoietic cells in most transplantation models, [30] [31] [32] [33] [34] and that ex vivo transduction of the graft impairs the repopulating ability of the graft. However, whether there is a threshold level of engraftment of transduced cells for tolerance induction still needs to be elucidated. Our results may contribute towards a better understanding of this important question. Levels of engraftment above 5% have been reported in mice receiving 70 cGy and 0.5 × 10 6 Sca-1 + BM cells, 33 and levels above 60% in mice receiving 100 cGy and 40 × 10 6 BM cells. 35 Transduced autologous or syngeneic hematopoietic grafts have to overcome weaker immune barriers than allogeneic ones, but they may not be completely invisible to a competent immune system. In fact, cells expressing transgenes can trigger cytotoxic (CTL) responses when transplanted into immunocompetent animals. 36, 37 Conversely, specific tolerance is often induced when foreign genes are stably expressed in HSC. Several reports describe long-term survival of transduced hematopoietic cells in partially ablated or even non-myeloablated experimental mice, 38,39 dogs 40 and non-human primates. 18, 34, 41 On the other hand, at least two studies describe the induction of immune responses to transgene expressing cells after autologous hematopoietic transplantation in non-ablated dogs, 42 and in sublethally irradiated non-human primates. 43 The possibility that the strain of mice used in this study (C57BL/6J) could be intrinsically tolerant to EGFP can be ruled out because this protein was reported to be highly immunogenic when expressed in tumorigenic cells injected into these mice. 36 Interestingly, in our experiments the percentages of EGFP + cells in the population of donor origin (CD45.1 + ) were similar in all groups of engrafted mice, irrespective of the dose of TBI administered or the level of engraftment achieved, which suggests that immune responses to EGFP + cells in these animals are either absent or very weak, even in those with microchimerism (see Figure 3) . In fact, four animals receiving 3 Gy and transplanted with 0.5 × 10 6 transduced cells had a 0.3% mean engraftment in the BM, of which 78.5% on average expressed the transgene 5 months after transplantation (one recipient had 0.05% of engraftment and 64% of the donor cells were EGFP + ). Kang et al 39 recently reported long-term survival of transduced hematopoietic cells in mice conditioned with 100 cGy of TBI and transplanted with 120 × 10 6 donor cells. However, in this study, none of the recipients was microchimeric (their engraftment rates ranged from 9.6 to 47.1%). 39 Although our results do not constitute a proof, they strongly suggest that the threshold level of EGFP expression in the hematopoietic system required to induce immune tolerance, at least in this model, is probably very low. The most likely explanation for this tolerance is that EGFP-expressing donorderived dendritic cells or other antigen-presenting cells migrating to the thymus contribute to delete T cells recognizing the new 'self' antigen. This strategy can be applied not only to diseases that do not need a total correction at the stem cell level, but also as a relatively non-toxic procedure to induce tolerance to the transgene products in non-hematopoietic gene therapies or to an allogeneic donor in organ transplantation.
The observation that the engraftment advantage of fresh over transduced marrow cells become more pronounced as the irradiation dose goes down (see Table 1 ) is also of interest and supports the rationale of minimizing ex vivo manipulation and increasing the graft size at low irradiation doses.
Stem cell gene therapy faces additional problems that also need to be addressed. In concordance with previous reports, we show that exposure to the 4-day transduction protocol resulted in an overall three-fold reduction in the repopulating ability of the grafts in comparison to that of fresh BM. This might be due to a loss of HSC during the transduction procedure and/or a loss of functionality of these HSC, which suggest that ex vivo culture conditions were probably suboptimal. A reduced long-term engrafting and repopulating ability of murine hematopoietic grafts was reported after exposure to cytokines in normal and myeloablated hosts [19] [20] [21] 44, 45 and after cytokine-facilitated retroviral transduction into non-ablated hosts. 20 In our experiments, mice transplanted with nonmanipulated cells received the same number of cells as those transplanted with 0.5 × 10 6 transduced cells. However, the total number of cells decreased an average of 44% during the ex vivo culture period (data not shown), which might have enriched the percentage of HSC in the transduced grafts. In our experiments we treated the donor mice with 5-fluorouracil (5-FU), which has been reported to increase retroviral transduction, but also to impair hematopoietic engraftment. 26, 46, 47 However, this does not affect our results since all donor mice were treated the same way.
Success of stem cell gene therapies relies not only on the development of vectors allowing efficient, safe and stable gene transfer and expression, but also on the use of non-toxic strategies to facilitate the engraftment of the gene-modified hematopoietic cells and to avoid the appearance of immune responses to the transgene product. Such strategies may facilitate the use of safer and more durable hematopoietic and non-hematopoietic gene therapies, which are in many cases limited by the immunogenicity of the transgene product.
Materials and methods
Retroviral vector and producer cell line
Ecotropic NX-E packaging cells (provided by G Nolan, Stanford University, Stanford, CA, USA) were infected with supernatants of the PG13/EGFP7 cell line, a gibbon ape leukemia virus (GALV) pseudotyped vector-producing cell line containing the SF-EGFP1 retroviral vector, 5, 48 derived from the FMEV backbone (a hybrid vector containing sequences of the Friend mink cell focus-forming virus and the embryonic stem cell virus). 49 Single cells with intermediate or high level of green fluorescence were sorted and grown in 96-well cell-culture plates by using an EPICS ELITE-ESP cytometer (Coulter Electronics, Hialeah, FL, USA) equipped with an autoclone device. The clone exhibiting the highest viral titer, termed NX-E/EGFP16, was selected for further experiments.
Mice and TBI
Mice used were 7-to 9-week-old female C57Bl/6J (CD45.2, recipients), obtained from Criffa (Barcelona, Co source (Theratron 780, Compagnie General de Radiologie-General Electric) was used to deliver total-body gamma irradiation (1.25 MeV). All irradiated animals were kept in isolators for at least 30 days after irradiation. Groups of five mice received either no myeloablation or a single dose of 1, 2, 3, 4, 5, 6, 7, 8 or 9 Gy of TBI (previously established as the lethal hematological dose for 95% of mice at 30 days (DL 95/30 )), at a constant dose rate of 50 cGy/min, less than 24 h before the infusion of the donor hematopoietic cells.
Isolation and retroviral transduction of murine BM cells BM cells were obtained by flushing the femora of the donor mice 5 days after 5-fluorouracil treatment (5-FU, 150 mg/kg i.p.) as previously described. 50 Preliminary studies were carried out to determine the optimal in vitro conditions for transducing murine hematopoietic progenitors. BM cells were either used fresh for transplantation, or cultured for 24 h in Iscove's modified Dulbecco's medium (IMDM) supplemented with 20% fetal calf serum (FCS), 200 mM glutamine, 50 IU/ml-50 g/ml penicillin-streptomycin, 10% of WEHI cells conditioned medium as a source of IL-3 51 and 8% of baby hamster kidney-murine c-kit ligand (BHK/MCL) cell line conditioned medium as a source of murine stem cell factor (mSCF) (a gift from S Tsai, Fred Hutchinson Cancer Research Center, Seattle, WA, USA) in six-well culture plates (TTP, Trasandingen, Switzerland) at a cell density of 0.5 × 10 6 mononuclear cells (MNC)/ml. For the following 2 days, 90% of the culture medium was replaced daily with filtered (0.45 m) supernatants of the NX-E/EGFP16 cell line, the corresponding volume of conditioned media and protamine sulfate (4 g/ml). At day 4 (24 h after the second infection cycle), BM cells were trypsinized, counted, and transduction efficiency was assessed by FACS analysis. An aliquot of cells was used for colony assays, and a total of either 0.5 × 10 6 or 5 × 10 6 cells were resuspended in 200 or 500 l phosphate buffered saline (PBS), respectively, and injected with a heparinized syringe in the tail vein of the recipient mice. Some animals were transplanted with 0.5 × 10 6 fresh non-manipulated marrow cells from 5-FU-treated donors.
FACS analysis
Twenty-four hours after the second transduction cycle, 2 × 10 5 cells were analyzed for EGFP expression by flow cytometry. Donor engraftment and EGFP expression were also analyzed in the PB of the transplanted mice 40 days after transplantation, and in the hematopoietic tissues (BM, PB and spleen) 5 months after transplantation. A minimum of 10 5 nucleated cells were incubated for 10 min at room temperature with 10% murine or rat serum and stained with phycoerythrin (PE)-conjugated anti-CD45.1 mAb (Becton-Dickinson, Franklin Lakes, NJ, USA) and biotinylated anti-CD45.2 (Becton Dickinson). After washing, cells were further stained with allophycocyanin (APC)-conjugated streptavidin (Becton Dickinson). After ammonium chloride erythrocyte lysis, cells were washed and resuspended in PBS solution containing 0.1% bovine serum albumin (BSA) and 0.01% sodium azide. 7-aminoactinomycin (7-AAD) 2 g/ml was then added before the four-color FACS analysis. Cells labeled with conjugated non-specific isotypic mAbs were used as controls. Cells were analyzed on a FACScalibur flow cytometer (Becton-Dickinson, San Jose, CA, USA 
Clonogenic assays
For the CFU assays, 2 × 10 5 fresh or 4-day cultured BM cells were diluted in 2 ml of complete medium containing 1% methylcellulose in Iscove's medium (Methocult H4100, Stem Cell Technologies, Vancouver, Canada), 30% FCS, 10% WEHI conditioned medium, 10% BSA (Life Technologies), 10 Ϫ4 mol/l ␤-mercaptoethanol, 200 mM Lglutamine, and 50 IU/ml-50 g/ml penicillin-streptomycin. Cells were plated and cultured for 14 days in a fully humidified atmosphere at 5% of CO 2 . Transduction efficiency was analyzed by measuring the percentage of green fluorescent colonies out of the total number of colonies using an inverted fluorescence microscope (IX70, Olympus, Japan) coupled to a UV lamp. Box plots, dot plots, and linear regression lines were generated using the software Sigmaplot (SPSS Science, Chicago, IL, USA).
Statistical analysis
Data are expressed as mean ± standard deviation (s.d.). Statistical comparisons were performed according to twotailed Student's t test (two groups), one way ANOVA (more than two groups), and Pearson's correlation coefficient (r). P values of Ͻ0.05, two-tailed, were considered significant. The relationship between long-term engraftment and the dose of TBI administered was determined by plotting all the XY data pairs and by comparing the linear regression lines corresponding to the three groups of mice (transplanted with 0.5 × 10 6 or 5 × 10 6 transduced BM cells, or with 0.5 × 10 6 non-manipulated BM cells). Statistical analysis of the data was performed using the Sigmastat software, release 2.0.
